Study guide
12.2 Common Exam Traps & Final Checklist
PTCB Hazardous Drug Management Certificate Exam
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
0.1 Exam Facts, Format & Eligibility 0.2 Content Outline, Scoring & Registration 0.3 USP <800> Big Picture & How to Use This Guide
2 USP <800> Program Administration
1.1 USP <800> Scope, Purpose & Enforcement 1.2 The NIOSH Hazardous Drug List (2024 Update) 1.3 Assessment of Risk 1.4 Designated Person, SOPs & the Hierarchy of Controls
3 Training, Compliance & Recordkeeping
2.1 Training Requirements & Medical Surveillance 2.2 Hazard Communication, SDS & OSHA Requirements 2.3 Recordkeeping & Professional Guidelines
4 Primary Engineering Controls
3.1 Containment Primary Engineering Controls (C-PEC): BSCs & CACIs 3.2 Closed System Transfer Devices (CSTDs) 3.3 Nonsterile Controls and the C-SCA Distinction
5 Secondary Engineering Controls & Facility Design
4.1 Containment Secondary Engineering Controls (C-SEC): Negative Pressure & Air Exchange 4.2 Facility Layout: Storage, Unpacking & Sink Placement 4.3 Certification, ISO Classes & Emergency Equipment
6 Facility Cleaning Procedures
5.1 The Four-Step Cleaning Process 5.2 Wipe Sampling & Action Levels 5.3 Hazardous Waste Disposal & RCRA
7 Spill Response & Cleaning PPE
6.1 Spill Kits & Spill Response Procedures 6.2 PPE During Cleaning: Glove Change Frequency & Disposal
8 Dispensing & the Compounding Interface
7.1 USP <795>/<797> Interface for Hazardous Drugs 7.2 High-Risk Oral Hazardous Drugs 7.3 Tablet Splitting & Crushing Restrictions
9 Counting, Packaging & Patient Counseling
8.1 Counting, Packaging & Dedicated Equipment 8.2 Patient Counseling & Unit-Dose Labeling
10 PPE: Gloves, Gowns & Task-Based Selection
9.1 ASTM D6978 Chemotherapy Gloves & Double Gloving 9.2 Chemo Gowns & Gown Change Frequency 9.3 Task-Based PPE Selection
11 Respiratory Protection, Eye Protection & PPE Sequencing
10.1 Respiratory & Eye/Face Protection 10.2 Donning & Doffing Sequence
12 Transport & Receiving
11.1 Receiving Hazardous Drug Shipments 11.2 Internal Transport & Storage 11.3 Damaged/Leaking Shipments & Chain of Custody
13 Exam Readiness & Final Review
12.1 Domain-by-Domain Quick Review 12.2 Common Exam Traps & Final Checklist
12.2 Common Exam Traps & Final Checklist
Key Takeaways Explain This Topic AI
The CSTD administration requirement concerns Table 1 antineoplastic HDs, a dosage form allowing use and a physically and chemically compatible device.
PPE depends on the task and exposure conditions; compounding requirements cannot be replaced by a universal single-glove rule for intact products.
If HD labelling gives no specific deactivation agent, the current USP FAQ directs an EPA-registered oxidizer rather than automatic omission of deactivation.
AoR alternatives require eligibility, drug/form-specific documentation and implementation; Table 1 placement and antineoplastic status are not identical.
The 55-question exam allows 80 minutes, plus a 5-minute tutorial and 5-minute survey; identification requirements depend on delivery mode and the stated conditions.
Last updated: October 2026
Check the condition that changes the answer
The distinctions below are an editorial review checklist, rather than a measured ranking of the most common PTCB questions. Practise explaining both the applicable rule and the assumption that makes a nearby alternative wrong. Keep the current PTCB outline and the January 2026 USP FAQ available for policy boundaries.
Distinction Condition to retain
CSTD required versus recommended Administration of Table 1 antineoplastic HDs, suitable dosage form and physical/chemical compatibility
Compounding PPE versus other handling Apply the stated activity's minimum requirements and the facility's additional risk-based protection
Deactivation versus disinfection Chemical hazard and microbial contamination require different measures
AoR eligibility versus a blanket waiver Identify the drug, dosage form and manipulation; document and implement allowed alternatives
Table 1 versus Table 2 Table placement is not identical to antineoplastic status or a complete handling instruction
Doffing versus donning in reverse Contain contamination in the required locations using the applicable procedure
1. CSTD: keep every qualifier
USP's administration requirement concerns NIOSH Table 1 antineoplastic HDs when the dosage form allows CSTD use , using a physically and chemically compatible device. Compounding carries a recommendation under this particular provision. Other applicable rules and facility requirements still matter.
Do not shorten this to “a CSTD is required for all HD tasks,” or to “a CSTD is always optional.” A question may change only the activity, classification or device compatibility, and that change can alter which statement is correct. A known incompatible device must not be used merely because CSTDs are protective in general. A CSTD also does not replace a required primary engineering control.
2. PPE: task and exposure conditions matter
The current FAQ specifies two pairs of ASTM D6978-tested gloves , an appropriate gown, head and hair covers and two pairs of shoe covers for HD compounding. The outer chemotherapy gloves must be sterile for sterile compounding. Do not reduce these requirements to a single pair of gloves because the HD happens to be a solid.
For administering Table 1 antineoplastic HDs, two pairs of chemotherapy gloves are required; for injectable administration, an HD-resistant gown is also required. For other activities, use the appropriate facility policy and exposure assessment instead of assuming that all intact products have one universal PPE configuration.
Change gloves when torn, punctured or contaminated. The chapter recommends changing chemotherapy gloves every 30 minutes unless the manufacturer's documentation recommends otherwise . Gown changes follow the manufacturer's permeation information; without that information, the chapter gives 2–3 hours , or immediately after a spill or splash. These are not interchangeable glove and gown clocks, and an immediate contamination event must not be ignored until an interval ends.
3. Surface treatment: do not skip a step by assumption
Deactivation addresses the drug's activity, decontamination removes HD residue, cleaning removes material from surfaces and disinfection addresses microorganisms. Sterile compounding areas require the subsequent disinfection step. Surface compatibility and the selected products' instructions remain essential.
USP's FAQ says to consult HD labelling for a specific deactivation agent and, if none is listed, use an EPA-registered oxidizer . It does not instruct a facility to omit deactivation automatically because no drug-specific agent appears in a question. Nor does it establish one universal chemical treatment effective against every HD.
If contamination remains, investigate the source and the effectiveness of the controls and cleaning process. Wipe sampling is recommended under USP, not a universal mandatory program; when it is performed, use the results and follow-up appropriately. Do not declare an arbitrary result “safe” by reference to a universal HD surface threshold that USP does not provide.
4. AoR: distinguish eligibility from implementation
Any HD API and a Table 1 antineoplastic requiring HD manipulation must follow the applicable containment requirements. Eligible final dosage forms, including final forms of compounded preparations, can instead be considered under the chapter's AoR provisions. Certain other HD dosage-form activities, including Table 2 reconstitution, mixing and dilution, may also be assessed.
Consequently, neither “all compounding is exempt” nor “any compounding eliminates AoR eligibility” is an adequate rule. Read the actual drug and form, the operation and any manufacturer requirement. An AoR must identify the drug and dosage form individually and its alternative strategies must be implemented; writing an assessment is not a substitute for using the resulting controls.
5. NIOSH tables: avoid false equivalences
The 2024 NIOSH Table 1 criteria include manufacturer's special handling information (MSHI) and/or the specified NTP “known” or IARC Group 1/2A classifications. A drug can therefore be in Table 1 because of MSHI without carrying one of those particular carcinogen classifications. Table 2 contains HDs that do not meet the Table 1 inclusion conditions; it is not a declaration of no occupational hazard.
Antineoplastics can occur in either table, and Table 1 contains non-antineoplastics. For USP's particular antineoplastic requirements, identify the Table 1 antineoplastic subset. Do not infer the full PPE and containment decision solely from a table number, while also retaining any specific provision that expressly uses that classification.
6. Doffing: location is part of the protection
Follow the trained, task-specific procedure to avoid spreading contaminated material. For sterile HD compounding, the January 2026 FAQ specifies removal of the outer sterile HD gloves inside the C-PEC . It describes removing the HD gown and outer shoe covers in the doffing area within the negative-pressure room , just before leaving, and handling the remaining PPE in the specified anteroom or general-area arrangement.
A single invented sequence such as “remove every item in the exact reverse of donning” does not capture those location conditions. Do not take contaminated disposable PPE into an unrelated clean area for convenience or reuse it later. The relevant instructions also govern hand hygiene, waste containment and any additional protection required for the work.
Prepare the appointment as carefully as the content
The current PTCB credential page specifies 55 multiple-choice questions and 80 minutes of exam time . It describes a 90-minute appointment comprising a five-minute tutorial, the 80-minute exam and a five-minute survey. Dividing 80 minutes by 55 gives about 87.3 seconds per question , an average planning figure rather than an item-by-item deadline or a reason to rush a complex question.
Use the official Pearson tutorial to become familiar with the interface and its available navigation features. During timed practice, record where you lose time, and leave room for a final check where the interface permits it. A third-party practice percentage or a preferred personal pace is not an official scaled-score conversion.
Check the current PTCB identification requirements for your delivery mode. The test-centre policy calls for an approved original, valid government-issued photo ID; a signature-bearing secondary ID is required when the primary lacks a signature. Do not assume that every candidate must always present two IDs. Online-proctored requirements and the stated exceptions must be checked separately.
Confirm the account-name match, appointment details, approved identification and any arrangements for accommodations before test day. PTCB directs both test-centre candidates and online candidates to arrive or begin check-in 30 minutes before the appointment . These logistical checks protect the opportunity to demonstrate what you have learned; they do not replace review across all six content domains.